In an IR interview, Kidswell Bio Corporation explained its growth strategy, which is built on two pillars: stable revenue from its biosimilar business and the development of cell therapies using SHED.
The company positions its biosimilar business as a stable source of revenue and is developing a cell therapy business using SHED. It is said to be pursuing a balance between stable income and growth investment while diversifying risk as a biotechnology venture.
According to its corporate history, the company was established in 2001 based on technology from Hokkaido University. It began its biosimilar business in 2012, when it sold its first product. In 2019, it also entered the cell therapy business using stem cells from human exfoliated deciduous teeth.
In its cell therapy business, the company is leveraging the characteristics of SHED. It is advancing the development of a treatment for cerebral palsy through clinical research with Nagoya University and cites its supply system, known as S-Quatre, as a strength. SHED are stem cells derived from dental pulp, and are said to offer the prospect of a stable supply because they can be collected when deciduous teeth are shed.
As a medium- to long-term growth target, the company aims to bring first-generation SHED therapies to clinical launch by 2030. It is strengthening its research capabilities, including by establishing new research centers, while using approvals for 4 biosimilar products to stabilize its revenue sources and accelerate SHED development.
For investors, management has expressed its intention to accelerate the cell therapy business, supported by the established earnings base of its biosimilar business. Kidswell Bio Corporation is said to be pursuing growth from a unique position.